We are monitoring the impact of COVID-19 on Gene Therapy Market Get in touch with us for detailed analysis Know More
Pulished Date April, 2021
ID: 10363
Share on
Share on

Global Gene Therapy Market Size, Share, Trends, COVID-19 Impact and Growth Analysis Report - Segmented By Vector Type, Application and Region (North America, Europe, Asia-Pacific, Latin America, Middle East, and Africa) - Industry Forecast (2021 to 2026)

Pulished: April, 2021
ID: 10363
Pages: 190

Gene Therapy Market Size (2021 to 2026)

The global gene therapy market size is forecasted to grow at a remarkable CAGR of 30.1% from 2021 to 2026. The market size is predicted to worth USD 19.88 billion by 2026 and USD 5.33 billion in 2021.

Gene therapy is an experimental method for treating or preventing illness by using genes. Gene therapies usually involve inserting a functional copy of a defective gene into the patient's cells. Genes are made up of DNA that contains the instructions for making proteins needed to function in the human body properly. Gene therapy is a treatment method that involves injecting DNA into a patient to cure genetic disorders. The new DNA has a working gene that can cure the symptoms of a disease that causes mutations. Repairing, repressing, and deleting defective genes are all part of gene therapy. Any neurological illnesses, such as muscular dystrophy and cystic fibrosis, and some hereditary conditions, tumors, and viral infections, may recover from this therapy. Since it helps correct the condition at the root DNA, this form of treatment is often referred to as a single-dose remedy. Several gene therapies for basic (single defect) and complicated genetic diseases have been developed over time. To date, ten gene therapies have been licensed (recent examples include Zolgensma, ZyntegloTM, and Collategene), and over a thousand product candidates are being tested in clinical trials around the world.

MARKET DRIVERS:

The rapid R &D in this market is expected to lead to the commercialization of the global gene therapy market and further increase gene therapy popularity.

Gene therapy is an essential area of the pharmaceutical industry and will grow in terms of market share in the future at a fast pace. Significant developments in molecular biology and cellular biology worldwide are primarily driving the growth of the global gene therapy market. The increase in population has led to a rise in chronic diseases, which is estimated to impact the market positively. The growing cases of cancer have fuelled the research and development being done for the market. The availability of reimbursements is another significant factor accelerating the growth rate of the market.

The development of technology due to increasing government initiatives has made it possible to commercialize the gene therapy market so that more and more private firms enter the market. The collaborations between private firms to develop gene therapy technology will increase the global gene therapy market growth during the forecast period. Gene therapy is also less risky than traditional methods, according to historical data.

MARKET RESTRAINTS:

Lack of skilled professionals such as scientists and doctors, high cost of product development, stringent regulatory policies, side effects like unwanted immune responses, and concerns regarding the unethical use of gene therapy are the factors that could largely impact the growth of the market of gene therapy in the coming years. Despite the rising prevalence of chronic diseases such as SMA and cancer, care remains prohibitively costly. The procedure is marketed as a single-dose therapy that corrects a hereditary deficiency in the patient's body. According to Novartis AG, a single dose of Kymriah, a cancer treatment drug, costs USD 475,000. The same drug is priced at USD 306,000 in Japan. High cost associated with the treatment; the budget challenge has reduced the healthcare expenditure. All these factors are expected to hamper the market growth to a small extent.

MARKET OPPORTUNITIES:

The growth of the gene therapy market is regulated for various reasons, including the rapid use of synthetically engineered genes to cure different disorders, the ability to devise customized medicine, and an increase in gene therapy research and development, others, fewer doses of medicines. It is a one-time treatment, and these factors are likely to create significant growth opportunities for the gene therapy market in the near future. An increase in support and spending for gene therapy advances is projected to create substantial business gains for the companies operating in this space. For Instance, REGENXBIO, Inc. and Ultragenyx Pharmaceutical, Inc. partnered in March 2020 to use the NAV technology platform. The latter organization obtained a worldwide license to REGENXBIO's NAV AAV9 and AAV8 vectors to advance gene therapies for a rare metabolic disease as part of this collaboration.

MARKET CHALLENGES:

The complications associated with gene therapy are a major challenge to overcome for this market to shine further. Unwanted immune system response, a gene cannot be easily injected directly into the cells, newly released viruses may be seen as intruders by your immune system, which can target them, by focusing on the infection of the wrong cells infects you, and you become infected, the possibility of tumor formation. Despite all of this therapeutic and commercial promise, cell and gene therapy researchers face challenges in many main areas, including allowing patient access, controlling the supply chain and manufacturing processes, and building a health care provider network, as with any modern and revolutionary, transformative technology.

Impact of COVID-19 on the global Gene Therapy Market:

COVID-19 pandemic created a positive impact on the market will increase the growth rate further during the forecast period. Gene therapy can treat the body from the virus's influence as the virus has affected people already underlying diseases. It has been observed that COVID-19 enhances the underlying disease's effects if the positive person has any. Research is being done so that gene therapy can become useful during this pandemic. Research Institutes have also been granted access funds for R&D in this field, which will further propel the market.

REPORT COVERAGE:

REPORT METRIC

DETAILS

Market Size Available

2020 to 2026

Base Year

2020

Forecast Period

2021 to 2026

Segments Covered

By Vector Type, Application, and Region

Various Analyses Covered

Global, Regional & Country Level Analysis, Segment-Level Analysis, Drivers, Restraints, Opportunities, Challenges, PESTLE Analysis, Porter’s Five Forces Analysis, Competitive Landscape, Analyst Overview on Investment Opportunities

Regions Covered

North America, Europe, Asia Pacific, Latin America, Middle East, and Africa

 

This market research report on the global gene therapy market has been segmented and sub-segmented based on vector type, application, and region.

Gene Therapy Market – By Vector Type:

  • Viral vector
    • Retroviruses
    • Lentiviruses
    • Adenoviruses
    • Adeno-associated Virus
    • Herpes Simplex Virus
    • Poxvirus
    • Vaccinia Virus
    • Others
  • Non-viral vector
    • Naked/Plasmid Vectors
    • Gene Gun
    • Electroporation
    • Lipofection
    • Others

The viral vector had the largest market share in 2020 and is expected to grow at a reasonable rate during the forecast period. It is further divided into eight sub-segments. The key factor responsible for this increasing growth rate is the more accessible genetic modifications such as Lentivirus, Adeno-Associated Virus (AAV) to deliver gene therapy drugs. With the high accuracy in delivering the gene to the region of interest, the demand for adeno-associated viruses (AAV) as a platform for gene therapy delivery is expected to increase during the forecast period. Lentivirus in the viral vector segment is expected to grow at the highest rate among its peers during the forecast period. The main reason for the high growth in companies that offer an exclusive Lentivector platform to key gene therapy developers.

The non-viral sector is expected to grow at the fastest rate during the forecast period. Advancements in physicochemical approaches will drive the growth of this subsegment. These approaches include physical methods and chemical methods of the non-viral vector for gene therapies used during the clinical trials and treatment process. 

Gene Therapy Market – By Application:

  • Oncological Disorders
  • Rare Diseases
  • Cardiovascular Diseases
  • Neurological Disorders
  • Infectious disease
  • Other Diseases

Based on the application, the oncological disorders segment had contributed the highest in revenue in 2019 and is expected to grow at a healthy rate during the forecast period. The main reason is the increasing number of cases of cancer around the world. The government has now contributed to the development by increasing regulatory approval of gene therapy for cancer. The improvement in technology is the key factor that will drive growth.

The cardiovascular disease sub-segment is expected to grow at the highest rate during the forecast period. The growing cases of cardiovascular diseases due to the prevalence of unhealthy lifestyles are the main reasons for growth. Improvement in healthcare facilities and rising awareness among people have positively impacted the development of the market.

The infectious disease segment is also expected to grow at a prominent rate during the forecast period. The main reason being the prevalence of coronavirus. The government's increase in funding to research institutes to develop the technology will drive the sub-segment growth. 

Gene Therapy Market – By Region:

  • North America
  • Europe
  • Asia Pacific
  • Latin America
  • Middle East and Africa

Regionally, North America held the largest share in 2019 in the global gene therapy market, with the growth rate expected to be high during the forecast period. An increase in the geriatric population and the prevalence of chronic diseases are significant growth contributing factors. The increased approvals from the Government bodies accepting the gene therapy process will motivate other notable players in the market.

Europe had the second largest market share and will grow at a promising rate during the forecast period, mainly due to increased chronic diseases and improved healthcare facilities in European countries.

The Asia Pacific is expected to grow at the fastest rate during the forecast period. The increase in population in India and China is the major contributing factor in the growth rate. The Asia Pacific market for gene therapy is estimated to witness a double-digit growth rate over the forecast period. Increasing adoption by the government and rising approvals will help the market to grow.

KEY MARKET PARTICIPANTS:

Biogen, Sarepta Therapeutics, Gilead Sciences, Inc., Amgen, Inc., Novartis AG, Orchard Therapeutics Plc, Spark Therapeutics, Inc., Molmed S.P.A., Anges, Inc., Bluebird Bio, Inc., Jazz Pharmaceuticals Plc, Dynavax Technologies, Human Stem Cells Institute, Sibiono Genetech Co., Ltd., Shanghai Sunway Biotech Co., Ltd., Uniqure N.V., Gensight Biologics S.A., Celgene Corporation, Cellectis, Sangamo Therapeutics, Mustang Bio, Applied Genetic Technologies Corporation and Poseida Therapeutics, Inc. are the dominating companies in the global gene therapy market.

KEY HAPPENINGS IN THIS MARKET:

  1. INTRODUCTION
    1. Market Definition
    2. Study Deliverables
    3. Base Currency, Base Year and Forecast Periods
    4. General Study Assumptions
  2. RESEARCH METHODOLOGY
    1. Introduction
    2. Research Phases
      1. Secondary Research
      2. Primary Research
      3. Econometric Modelling
      4. Expert Validation
    3. Analysis Design
    4. Study Timeline
  3. Report Overview
    1. Executive Summary
    2. Key Inferences
  4. Market Dynamics
    1. Impact Analysis
      1. Drivers
      2. Restraints
      3. Opportunities       
    2. Regulatory Environment
    3. Technology Timeline & Recent Trends
  5. Competitor Benchmarking Analysis
    1. Key Player Benchmarking                    
      1. Market share analysis      
      2. Products/Service
      3. Regional Presence               
    2. Mergers & Acquisition Landscape                     
    3. Joint Ventures & Collaborations
  6. MARKET SEGMENTATION
    1. By Vector Type
      1. Viral vector
        1. Retroviruses
        2. Lentiviruses
        3. Adenoviruses
        4. Adeno-associated Virus
        5. Herpes Simplex Virus
        6. Poxvirus
        7. Vaccinia Virus
        8. Others
      2. Non-viral vector
        1. Naked/Plasmid Vectors
        2. Gene Gun
        3. Electroporation
        4. Lipofection
        5. Others
      3. Y-o-Y Growth Analysis, By Vector Type
      4. Market Attractiveness Analysis, By Vector Type
      5. Market Share Analysis, By Vector Type
    2. By Application
      1. Oncological Disorders
      2. Rare Diseases
      3. Cardiovascular Diseases
      4. Neurological Disorders
      5. Infectious disease
      6. Other Diseases
      7. Y-o-Y Growth Analysis, By Application
      8. Market Attractiveness Analysis, By Application
      9. Market Share Analysis, By Application
  7. GEOGRAPHICAL ANALYSIS
    1. Introduction
      1. Regional Trends
      2. Impact Analysis
      3. Y-o-Y Growth Analysis
      4. Market Attractiveness Analysis
      5. Market Share Analysis
    2. North America
      1. Introduction
      2. United States
      3. Canada
    3. Europe
      1. Introduction
      2. U.K
      3. Spain
      4. Germany
      5. Italy
      6. France
      7. Rest of Europe
    4. Asia-Pacific
      1. Introduction
      2. China
      3. India
      4. Japan
      5. South Korea
      6. Australia and NZ
      7. Rest of APAC
    5. Latin America
      1. Introduction
      2. Brazil
      3. Argentina
      4. Mexico
      5. Rest of Latin America
    6. Middle East & Africa
      1. Introduction
      2. Middle-East
      3. Africa
  8. STRATEGIC ANALYSIS
    1. PESTLE analysis
      1. Political
      2. Economic
      3. Social
      4. Technological
      5. Legal
      6. Environmental
    2. Porter’s Five analysis
      1. Bargaining Power of Suppliers
      2. Bargaining Power of Consumers
      3. Threat of New Entrants
      4. Threat of Substitute Products and Services
      5. Competitive Rivalry within the Industry
  9. MARKET LEADERS' ANALYSIS
    1. Biogen
      1. Overview
      2. Products
      3. Financials (subjected to availability based on company type)
      4. Recent Developments
      5. SWOT analysis
      6. Analyst View
    2. Sarepta Therapeutics
    3. Gilead Sciences, Inc.
    4. Amgen, Inc.
    5. Novartis AG
    6. Orchard Therapeutics Plc
    7. Spark Therapeutics, Inc.
    8. Molmed S.P.A.
    9. Anges, Inc.
    10. Bluebird Bio, Inc.
    11. Jazz Pharmaceuticals Plc
    12. Dynavax Technologies
    13. Human Stem Cells Institute
    14. Sibiono Genetech Co., Ltd.
    15. Shanghai Sunway Biotech Co., Ltd.
    16. Uniqure N.V.
    17. Gensight Biologics S.A.
    18. Celgene Corporation
    19. Cellectis
    20. Sangamo Therapeutics
    21. Mustang Bio
    22. Applied Genetic Technologies Corporation
    23. Poseida Therapeutics, Inc.
  10. COMPETITIVE LANDSCAPE
    1. Market share analysis
    2. Merger and Acquisition Analysis
    3. Agreements, collaborations and Joint Ventures
    4. New Product Launches
  11. MARKET OUTLOOK AND INVESTMENT OPPORTUNITIES
  12. APPENDIX
  13. List of Tables
  14. List of Figures
  • Global, regional and country-level analysis and forecasts of the study market; providing Insights on the major countries/regions in which this industry is blooming and to also identify the regions that are still untapped
  • Segment-level analysis in terms of vector type and application along with market size forecasts and estimations to detect key areas of industry growth in detail
  • Identification of key drivers, restraints, opportunities, and challenges (DROC) in the market and their impact on shifting market dynamics
  • Study of the effect of exogenous and endogenous factors that affect the global market; which includes broadly demographic, economics, and political, among other macro-environmental factors presented in an extensive PESTLE Analysis
  • Study the micro environment factors that determine the overall profitability of an Industry, using Porter’s five forces analysis for analysing the level of competition and business strategy development
  • A comprehensive list of key market players along with their product portfolio, current strategic interests, key financial information, legal issues, SWOT analysis and analyst overview to study and sustain the market environment
  • Competitive landscape analysis listing out the mergers, acquisitions, collaborations in the field along with new product launches, comparative financial studies and recent developments in the market by the major companies
  • An executive summary, abridging the entire report in such a way that decision-making personnel can rapidly become acquainted with background information, concise analysis and main conclusions
  • Expertly devised analyst overview along with Investment opportunities to provide both individuals and organizations a strong financial foothold in the market
  1. Global Gene Therapy Market, By Region, From 2021 to 2026 (USD Billion)
  2. Global Gene Therapy Market, By Vector Type, From 2021 to 2026 (USD Billion)
  3. Global Viral vector Market, By Region, From 2021 to 2026 (USD Billion)
  4. Global Non-viral vector Market, By Region, From 2021 to 2026 (USD Billion)
  5. Global Gene Therapy Market, By Application, From 2021 to 2026 (USD Billion)
  6. Global Oncological Disorders Market, By Region, From 2021 to 2026 (USD Billion)
  7. Global Rare Diseases Market, By Region, From 2021 to 2026 (USD Billion)
  8. Global Cardiovascular Diseases Market, By Region, From 2021 to 2026 (USD Billion)
  9. Global Neurological Disorders Market, By Region, From 2021 to 2026 (USD Billion)
  10. Global Infectious disease Market, By Region, From 2021 to 2026 (USD Billion)
  11. Global Other Diseases Market, By Region, From 2021 to 2026 (USD Billion)
  12. Global Gene Therapy Market, By Viral vector, From 2021 to 2026 (USD Billion)
  13. Global Retroviruses Market, By Region, From 2021 to 2026 (USD Billion)
  14. Global Lentiviruses Market, By Region, From 2021 to 2026 (USD Billion)
  15. Global Adenoviruses Market, By Region, From 2021 to 2026 (USD Billion)
  16. Global Adeno-associated Virus Market, By Region, From 2021 to 2026 (USD Billion)
  17. Global Herpes Simplex Virus Market, By Region, From 2021 to 2026 (USD Billion)
  18. Global Poxvirus Market, By Region, From 2021 to 2026 (USD Billion)
  19. Global Vaccinia Virus Market, By Region, From 2021 to 2026 (USD Billion)
  20. Global Gene Therapy Market, By Non-viral vector, From 2021 to 2026 (USD Billion)
  21. Global Naked/Plasmid Vectors Market, By Region, From 2021 to 2026 (USD Billion)
  22. Global Gene Gun Market, By Region, From 2021 to 2026 (USD Billion)
  23. Global Electroporation Market, By Region, From 2021 to 2026 (USD Billion)
  24. Global Lipofection Market, By Region, From 2021 to 2026 (USD Billion)
  25. Global Others Market, By Region, From 2021 to 2026 (USD Billion)
  26. North America Gene Therapy Market, By Vector Type, From 2021 to 2026 (USD Billion)
  27. North America Viral vector Market, By Region, From 2021 to 2026 (USD Billion)
  28. North America Non-viral vector Market, By Region, From 2021 to 2026 (USD Billion)
  29. North America Gene Therapy Market, By Application, From 2021 to 2026 (USD Billion)
  30. North America Oncological Disorders Market, By Region, From 2021 to 2026 (USD Billion)
  31. North America Rare Diseases Market, By Region, From 2021 to 2026 (USD Billion)
  32. North America Cardiovascular Diseases Market, By Region, From 2021 to 2026 (USD Billion)
  33. North America Neurological Disorders Market, By Region, From 2021 to 2026 (USD Billion)
  34. North America Infectious disease Market, By Region, From 2021 to 2026 (USD Billion)
  35. North America Other Diseases Market, By Region, From 2021 to 2026 (USD Billion)
  36. United States Gene Therapy Market, By Vector Type, From 2021 to 2026 (USD Billion)
  37. United States Gene Therapy Market, By Application, From 2021 to 2026 (USD Billion)
  38. Canada Gene Therapy Market, By Vector Type, From 2021 to 2026 (USD Billion)
  39. Canada Gene Therapy Market, By Application, From 2021 to 2026 (USD Billion)
  40. North America Gene Therapy Market, By Viral vector, From 2021 to 2026 (USD Billion)
  41. North America Retroviruses Market, By Region, From 2021 to 2026 (USD Billion)
  42. North America Lentiviruses Market, By Region, From 2021 to 2026 (USD Billion)
  43. North America Adenoviruses Market, By Region, From 2021 to 2026 (USD Billion)
  44. North America Adeno-associated Virus Market, By Region, From 2021 to 2026 (USD Billion)
  45. North America Herpes Simplex Virus Market, By Region, From 2021 to 2026 (USD Billion)
  46. North America Poxvirus Market, By Region, From 2021 to 2026 (USD Billion)
  47. North America Vaccinia Virus Market, By Region, From 2021 to 2026 (USD Billion)
  48. United States Gene Therapy Market, By Viral vector, From 2021 to 2026 (USD Billion)
  49. Canada Gene Therapy Market, By Viral vector, From 2021 to 2026 (USD Billion)
  50. North America Gene Therapy Market, By Non-viral vector, From 2021 to 2026 (USD Billion)
  51. North America Naked/Plasmid Vectors Market, By Region, From 2021 to 2026 (USD Billion)
  52. North America Gene Gun Market, By Region, From 2021 to 2026 (USD Billion)
  53. North America Electroporation Market, By Region, From 2021 to 2026 (USD Billion)
  54. North America Lipofection Market, By Region, From 2021 to 2026 (USD Billion)
  55. North America Others Market, By Region, From 2021 to 2026 (USD Billion)
  56. United States Gene Therapy Market, By Non-viral vector, From 2021 to 2026 (USD Billion)
  57. Canada Gene Therapy Market, By Non-viral vector, From 2021 to 2026 (USD Billion)
  58. Europe Gene Therapy Market, By Vector Type, From 2021 to 2026 (USD Billion)
  59. Europe Viral vector Market, By Region, From 2021 to 2026 (USD Billion)
  60. Europe Non-viral vector Market, By Region, From 2021 to 2026 (USD Billion)
  61. Europe Gene Therapy Market, By Application, From 2021 to 2026 (USD Billion)
  62. Europe Oncological Disorders Market, By Region, From 2021 to 2026 (USD Billion)
  63. Europe Rare Diseases Market, By Region, From 2021 to 2026 (USD Billion)
  64. Europe Cardiovascular Diseases Market, By Region, From 2021 to 2026 (USD Billion)
  65. Europe Neurological Disorders Market, By Region, From 2021 to 2026 (USD Billion)
  66. Europe Infectious disease Market, By Region, From 2021 to 2026 (USD Billion)
  67. Europe Other Diseases Market, By Region, From 2021 to 2026 (USD Billion)
  68. U.K. Gene Therapy Market, By Vector Type, From 2021 to 2026 (USD Billion)
  69. U.K. Gene Therapy Market, By Application, From 2021 to 2026 (USD Billion)
  70. Germany Gene Therapy Market, By Vector Type, From 2021 to 2026 (USD Billion)
  71. Germany Gene Therapy Market, By Application, From 2021 to 2026 (USD Billion)
  72. France Gene Therapy Market, By Vector Type, From 2021 to 2026 (USD Billion)
  73. France Gene Therapy Market, By Application, From 2021 to 2026 (USD Billion)
  74. Italy Gene Therapy Market, By Vector Type, From 2021 to 2026 (USD Billion)
  75. Italy Gene Therapy Market, By Application, From 2021 to 2026 (USD Billion)
  76. Spain Gene Therapy Market, By Vector Type, From 2021 to 2026 (USD Billion)
  77. Spain Gene Therapy Market, By Application, From 2021 to 2026 (USD Billion)
  78. Europe Gene Therapy Market, By Viral vector, From 2021 to 2026 (USD Billion)
  79. Europe Retroviruses Market, By Region, From 2021 to 2026 (USD Billion)
  80. Europe Lentiviruses Market, By Region, From 2021 to 2026 (USD Billion)
  81. Europe Adenoviruses Market, By Region, From 2021 to 2026 (USD Billion)
  82. Europe Adeno-associated Virus Market, By Region, From 2021 to 2026 (USD Billion)
  83. Europe Herpes Simplex Virus Market, By Region, From 2021 to 2026 (USD Billion)
  84. Europe Poxvirus Market, By Region, From 2021 to 2026 (USD Billion)
  85. Europe Vaccinia Virus Market, By Region, From 2021 to 2026 (USD Billion)
  86. U.K. Gene Therapy Market, By Viral vector, From 2021 to 2026 (USD Billion)
  87. Germany Gene Therapy Market, By Viral vector, From 2021 to 2026 (USD Billion)
  88. France Gene Therapy Market, By Viral vector, From 2021 to 2026 (USD Billion)
  89. Italy Gene Therapy Market, By Viral vector, From 2021 to 2026 (USD Billion)
  90. Spain Gene Therapy Market, By Viral vector, From 2021 to 2026 (USD Billion)
  91. Europe Gene Therapy Market, By Non-viral vector, From 2021 to 2026 (USD Billion)
  92. Europe Naked/Plasmid Vectors Market, By Region, From 2021 to 2026 (USD Billion)
  93. Europe Gene Gun Market, By Region, From 2021 to 2026 (USD Billion)
  94. Europe Electroporation Market, By Region, From 2021 to 2026 (USD Billion)
  95. Europe Lipofection Market, By Region, From 2021 to 2026 (USD Billion)
  96. Europe Others Market, By Region, From 2021 to 2026 (USD Billion)
  97. U.K. Gene Therapy Market, By Non-viral vector, From 2021 to 2026 (USD Billion)
  98. Germany Gene Therapy Market, By Non-viral vector, From 2021 to 2026 (USD Billion)
  99. France Gene Therapy Market, By Non-viral vector, From 2021 to 2026 (USD Billion)
  100. Italy Gene Therapy Market, By Non-viral vector, From 2021 to 2026 (USD Billion)
  101. Spain Gene Therapy Market, By Non-viral vector, From 2021 to 2026 (USD Billion)
  102. Asia Pacific Gene Therapy Market, By Vector Type, From 2021 to 2026 (USD Billion)
  103. Asia Pacific Viral vector Market, By Region, From 2021 to 2026 (USD Billion)
  104. Asia Pacific Non-viral vector Market, By Region, From 2021 to 2026 (USD Billion)
  105. Asia Pacific Gene Therapy Market, By Application, From 2021 to 2026 (USD Billion)
  106. Asia Pacific Oncological Disorders Market, By Region, From 2021 to 2026 (USD Billion)
  107. Asia Pacific Rare Diseases Market, By Region, From 2021 to 2026 (USD Billion)
  108. Asia Pacific Cardiovascular Diseases Market, By Region, From 2021 to 2026 (USD Billion)
  109. Asia Pacific Neurological Disorders Market, By Region, From 2021 to 2026 (USD Billion)
  110. Asia Pacific Infectious disease Market, By Region, From 2021 to 2026 (USD Billion)
  111. Asia Pacific Other Diseases Market, By Region, From 2021 to 2026 (USD Billion)
  112. Japan Gene Therapy Market, By Vector Type, From 2021 to 2026 (USD Billion)
  113. Japan Gene Therapy Market, By Application, From 2021 to 2026 (USD Billion)
  114. China Gene Therapy Market, By Vector Type, From 2021 to 2026 (USD Billion)
  115. China Gene Therapy Market, By Application, From 2021 to 2026 (USD Billion)
  116. India Gene Therapy Market, By Vector Type, From 2021 to 2026 (USD Billion)
  117. India Gene Therapy Market, By Application, From 2021 to 2026 (USD Billion)
  118. Australia Gene Therapy Market, By Vector Type, From 2021 to 2026 (USD Billion)
  119. Australia Gene Therapy Market, By Application, From 2021 to 2026 (USD Billion)
  120. South Korea Gene Therapy Market, By Vector Type, From 2021 to 2026 (USD Billion)
  121. South Korea Gene Therapy Market, By Application, From 2021 to 2026 (USD Billion)
  122. Asia Pacific Gene Therapy Market, By Viral vector, From 2021 to 2026 (USD Billion)
  123. Asia Pacific Retroviruses Market, By Region, From 2021 to 2026 (USD Billion)
  124. Asia Pacific Lentiviruses Market, By Region, From 2021 to 2026 (USD Billion)
  125. Asia Pacific Adenoviruses Market, By Region, From 2021 to 2026 (USD Billion)
  126. Asia Pacific Adeno-associated Virus Market, By Region, From 2021 to 2026 (USD Billion)
  127. Asia Pacific Herpes Simplex Virus Market, By Region, From 2021 to 2026 (USD Billion)
  128. Asia Pacific Poxvirus Market, By Region, From 2021 to 2026 (USD Billion)
  129. Asia Pacific Vaccinia Virus Market, By Region, From 2021 to 2026 (USD Billion)
  130. Japan Gene Therapy Market, By Viral vector, From 2021 to 2026 (USD Billion)
  131. China Gene Therapy Market, By Viral vector, From 2021 to 2026 (USD Billion)
  132. India Gene Therapy Market, By Viral vector, From 2021 to 2026 (USD Billion)
  133. Australia Gene Therapy Market, By Viral vector, From 2021 to 2026 (USD Billion)
  134. Asia Pacific Gene Therapy Market, By Non-viral vector, From 2021 to 2026 (USD Billion)
  135. Asia Pacific Naked/Plasmid Vectors Market, By Region, From 2021 to 2026 (USD Billion)
  136. Asia Pacific Gene Gun Market, By Region, From 2021 to 2026 (USD Billion)
  137. Asia Pacific Electroporation Market, By Region, From 2021 to 2026 (USD Billion)
  138. Asia Pacific Lipofection Market, By Region, From 2021 to 2026 (USD Billion)
  139. Asia Pacific Others Market, By Region, From 2021 to 2026 (USD Billion)
  140. Japan Gene Therapy Market, By Non-viral vector, From 2021 to 2026 (USD Billion)
  141. China Gene Therapy Market, By Non-viral vector, From 2021 to 2026 (USD Billion)
  142. India Gene Therapy Market, By Non-viral vector, From 2021 to 2026 (USD Billion)
  143. Australia Gene Therapy Market, By Non-viral vector, From 2021 to 2026 (USD Billion)
  144. Latin America Gene Therapy Market, By Vector Type, From 2021 to 2026 (USD Billion)
  145. Latin America Viral vector Market, By Region, From 2021 to 2026 (USD Billion)
  146. Latin America Non-viral vector Market, By Region, From 2021 to 2026 (USD Billion)
  147. Latin America Gene Therapy Market, By Application, From 2021 to 2026 (USD Billion)
  148. Latin America Oncological Disorders Market, By Region, From 2021 to 2026 (USD Billion)
  149. Latin America Rare Diseases Market, By Region, From 2021 to 2026 (USD Billion)
  150. Latin America Cardiovascular Diseases Market, By Region, From 2021 to 2026 (USD Billion)
  151. Latin America Neurological Disorders Market, By Region, From 2021 to 2026 (USD Billion)
  152. Latin America Infectious disease Market, By Region, From 2021 to 2026 (USD Billion)
  153. Latin America Other Diseases Market, By Region, From 2021 to 2026 (USD Billion)
  154. Brazil Gene Therapy Market, By Vector Type, From 2021 to 2026 (USD Billion)
  155. Brazil Gene Therapy Market, By Application, From 2021 to 2026 (USD Billion)
  156. Argentina Gene Therapy Market, By Vector Type, From 2021 to 2026 (USD Billion)
  157. Argentina Gene Therapy Market, By Application, From 2021 to 2026 (USD Billion)
  158. Mexico Gene Therapy Market, By Vector Type, From 2021 to 2026 (USD Billion)
  159. Mexico Gene Therapy Market, By Application, From 2021 to 2026 (USD Billion)
  160. Rest of Latin America Gene Therapy Market, By Vector Type, From 2021 to 2026 (USD Billion)
  161. Rest of Latin America Gene Therapy Market, By Application, From 2021 to 2026 (USD Billion)
  162. Latin America Gene Therapy Market, By Viral vector, From 2021 to 2026 (USD Billion)
  163. Latin America Retroviruses Market, By Region, From 2021 to 2026 (USD Billion)
  164. Latin America Lentiviruses Market, By Region, From 2021 to 2026 (USD Billion)
  165. Latin America Adenoviruses Market, By Region, From 2021 to 2026 (USD Billion)
  166. Latin America Adeno-associated Virus Market, By Region, From 2021 to 2026 (USD Billion)
  167. Latin America Herpes Simplex Virus Market, By Region, From 2021 to 2026 (USD Billion)
  168. Latin America Poxvirus Market, By Region, From 2021 to 2026 (USD Billion)
  169. Latin America Vaccinia Virus Market, By Region, From 2021 to 2026 (USD Billion)
  170. Brazil Gene Therapy Market, By Viral vector, From 2021 to 2026 (USD Billion)
  171. Argentina Gene Therapy Market, By Viral vector, From 2021 to 2026 (USD Billion)
  172. Mexico Gene Therapy Market, By Viral vector, From 2021 to 2026 (USD Billion)
  173. Latin America Gene Therapy Market, By Non-viral vector, From 2021 to 2026 (USD Billion)
  174. Latin America Naked/Plasmid Vectors Market, By Region, From 2021 to 2026 (USD Billion)
  175. Latin America Gene Gun Market, By Region, From 2021 to 2026 (USD Billion)
  176. Latin America Electroporation Market, By Region, From 2021 to 2026 (USD Billion)
  177. Latin America Lipofection Market, By Region, From 2021 to 2026 (USD Billion)
  178. Latin America Others Market, By Region, From 2021 to 2026 (USD Billion)
  179. Brazil Gene Therapy Market, By Non-viral vector, From 2021 to 2026 (USD Billion)
  180. Argentina Gene Therapy Market, By Non-viral vector, From 2021 to 2026 (USD Billion)
  181. Mexico Gene Therapy Market, By Non-viral vector, From 2021 to 2026 (USD Billion)
  182. Middle East and Africa Gene Therapy Market, By Vector Type, From 2021 to 2026 (USD Billion)
  183. Middle East and Africa Viral vector Market, By Region, From 2021 to 2026 (USD Billion)
  184. Middle East and Africa Non-viral vector Market, By Region, From 2021 to 2026 (USD Billion)
  185. Middle East and Africa Gene Therapy Market, By Application, From 2021 to 2026 (USD Billion)
  186. Middle East and Africa Oncological Disorders Market, By Region, From 2021 to 2026 (USD Billion)
  187. Middle East and Africa Rare Diseases Market, By Region, From 2021 to 2026 (USD Billion)
  188. Middle East and Africa Cardiovascular Diseases Market, By Region, From 2021 to 2026 (USD Billion)
  189. Middle East and Africa Neurological Disorders Market, By Region, From 2021 to 2026 (USD Billion)
  190. Middle East and Africa Infectious disease Market, By Region, From 2021 to 2026 (USD Billion)
  191. Middle East and Africa Other Diseases Market, By Region, From 2021 to 2026 (USD Billion)
  192. Middle East Gene Therapy Market, By Vector Type, From 2021 to 2026 (USD Billion)
  193. Middle East Gene Therapy Market, By Application, From 2021 to 2026 (USD Billion)
  194. Africa Gene Therapy Market, By Vector Type, From 2021 to 2026 (USD Billion)
  195. Africa Gene Therapy Market, By Application, From 2021 to 2026 (USD Billion)
  196. Middle East and Africa Gene Therapy Market, By Viral vector, From 2021 to 2026 (USD Billion)
  197. Middle East and Africa Retroviruses Market, By Region, From 2021 to 2026 (USD Billion)
  198. Middle East and Africa Lentiviruses Market, By Region, From 2021 to 2026 (USD Billion)
  199. Middle East and Africa Adenoviruses Market, By Region, From 2021 to 2026 (USD Billion)
  200. Middle East and Africa Adeno-associated Virus Market, By Region, From 2021 to 2026 (USD Billion)
  201. Middle East and Africa Herpes Simplex Virus Market, By Region, From 2021 to 2026 (USD Billion)
  202. Middle East and Africa Poxvirus Market, By Region, From 2021 to 2026 (USD Billion)
  203. Middle East and Africa Vaccinia Virus Market, By Region, From 2021 to 2026 (USD Billion)
  204. Middle East Gene Therapy Market, By Viral vector, From 2021 to 2026 (USD Billion)
  205. Africa Gene Therapy Market, By Viral vector, From 2021 to 2026 (USD Billion)
  206. Middle East and Africa Gene Therapy Market, By Non-viral vector, From 2021 to 2026 (USD Billion)
  207. Middle East and Africa Naked/Plasmid Vectors Market, By Region, From 2021 to 2026 (USD Billion)
  208. Middle East and Africa Gene Gun Market, By Region, From 2021 to 2026 (USD Billion)
  209. Middle East and Africa Electroporation Market, By Region, From 2021 to 2026 (USD Billion)
  210. Middle East and Africa Lipofection Market, By Region, From 2021 to 2026 (USD Billion)
  211. Middle East and Africa Others Market, By Region, From 2021 to 2026 (USD Billion)
  212. Middle East Gene Therapy Market, By Non-viral vector, From 2021 to 2026 (USD Billion)
  213. Africa Gene Therapy Market, By Non-viral vector, From 2021 to 2026 (USD Billion)

Please wait. . . . Your request is being processed

Related Reports

LICENCE TYPE

$ 1234 4255

Clients
clients
clients
clients
clients
clients
clients
Click for Request Sample